Skip to content

Released Mar 30, 2026, before the open

10-K filed Mar 30, 2026, 89 days after period end · 0001628280-26-022010

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$37.39MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$41,122,000N/M
Operating Cash Flowderived-$23,886,000N/M
Free Cash Flowderived-$24,124,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figures
Net Income-$37.39M-$20.96M-$12.44M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR